ReviewDiabetologia2015
Obesity, diabetes and cancer: insight into the relationship from a cohort with growth hormone receptor deficiency.
Review in Diabetologia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Risk of Esophageal Adenocarcinoma After Bariatric Surgery: A Meta-Analysis of Retrospective Studies.Obesity surgery · 2024Pooled it
- Growth Hormone Signaling in Bladder Cancer: Transcriptomic Profiling of Patient Samples and In Vitro Evidence of Therapy Resistance via ABC Transporters and EMT Activation.International journal of molecular sciences · 2025Article
- The Effect of Endotoxin-Induced Inflammation on the Activity of the Somatotropic Axis in Sheep.International journal of inflammation · 2024Article
- Unveiling the MUFA-Cancer Connection: Insights from Endogenous and Exogenous Perspectives.International journal of molecular sciences · 2023Review
- Divergent metabolic phenotypes in two genetic syndromes of low insulin secretion.Diabetes research and clinical practice · 2023Article
- Insights from the clinical phenotype of subjects with Laron syndrome in Ecuador.Reviews in endocrine & metabolic disorders · 2021Review
- GH/IGF-1 Abnormalities and Muscle Impairment: From Basic Research to Clinical Practice.International journal of molecular sciences · 2021Review
- Digital Health for Supporting Precision Medicine in Pediatric Endocrine Disorders: Opportunities for Improved Patient Care.Frontiers in pediatrics · 2021Review
- Evaluating the impact of AMPK activation, a target of metformin, on risk of cardiovascular diseases and cancer in the UK Biobank: a Mendelian randomisation study.Diabetologia · 2020Article
- Site-specific cancer risk in patients with type 2 diabetes: a nationwide population-based cohort study in Korea.The Korean journal of internal medicine · 2020Article
- Integrative Analyses of mRNA Expression Profile RevealFrontiers in genetics · 2020Article
- Loss of Adipose Growth Hormone Receptor in Mice Enhances Local Fatty Acid Trapping and Impairs Brown Adipose Tissue Thermogenesis.iScience · 2019Article
- Obesity, Insulin Resistance, and Colorectal Cancer: Could miRNA Dysregulation Play A Role?International journal of molecular sciences · 2019Review
- Growth hormone receptor-deficient pigs resemble the pathophysiology of human Laron syndrome and reveal altered activation of signaling cascades in the liver.Molecular metabolism · 2018Article
- Prevention of tumour cell apoptosis associated with sustained protein kinase B phosphorylation is more sensitive to regulation by insulin signalling than stimulation of proliferation and extracellular signal-regulated kinase.Molecular and cellular biochemistry · 2017Article
- Mushroom Polysaccharides: Chemistry and Antiobesity, Antidiabetes, Anticancer, and Antibiotic Properties in Cells, Rodents, and Humans.Foods (Basel, Switzerland) · 2016Review
- Hepatic Deletion of Janus Kinase 2 Counteracts Oxidative Stress in Mice.Scientific reports · 2016Article
- Review
- Dietary and pharmacological modification of the insulin/IGF-1 system: exploiting the full repertoire against cancer.Oncogenesis · 2016Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity with insulin-resistant diabetes and increased cancer risk is a global problem. We consider the alterations of metabolism attendant on the underlying pathogenic overnutrition and the role of the growth hormone (GH)-IGF-1 axis in this interaction. Obesity-induced insulin resistance is a determinant of diabetes. Excess glucose, and an elevated concentration of insulin acting through its own receptors along with complex interactions with the IGF-1 system, will add extra fuel and fuel signalling for malignant growth and induce anti-apoptotic activities, permitting proliferation of forbidden clones. In Ecuador there are ~100 living adults with lifelong IGF-1 deficiency caused by a GH receptor (GHR) mutation who, despite a high percentage of body fat, have markedly increased insulin sensitivity compared with age- and BMI-matched control relatives, and no instances of diabetes, which is present in 6% of unaffected relatives. Only 1 of 20 deceased individuals with GHR deficiency died of cancer vs 20% of ~1,500 relatives. Fewer DNA breaks and increased apoptosis occurred in cell cultures exposed to oxidant agents following addition of serum from GHR-deficient individuals vs serum from control relatives. These changes were reversible by adding IGF-1 to the serum from the GHR-deficient individuals. The reduction in central regulators of pro-ageing signalling thus appears to be the result of an absence of GHR function. The complex inter-relationship of obesity, diabetes and cancer risk is related to excess insulin and fuel supply, in the presence of heightened anti-apoptosis and uninhibited DNA damage when GHR function is normal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.